GLP-1 therapies are no longer being viewed only as diabetes treatments. The category is increasingly being discussed in relation to cardiovascular disease, chronic kidney disease, inflammatory bowel disease, metabolic dysfunction-associated steatohepatitis and broader metabolic health.
As evidence builds beyond glycaemic control, the commercial case for GLP-1 therapies becomes less dependent on a single treatment narrative. A therapy class with growing relevance across multiple conditions may support a more durable strategic position, particularly where metabolic disease overlaps with cardiovascular and inflammatory pathways.
The cardiovascular angle is one of the more established areas of this broader narrative. Research discussed in the source points to reduced risk of major cardiovascular events with certain GLP-1 receptor agonists in people with type 2 diabetes. Chronic kidney disease is also emerging as an area of interest, with studies exploring whether these therapies could improve kidney outcomes and slow progression.
Patients are becoming more aware of benefits that may extend beyond diabetes, while healthcare professionals are balancing new interest with the need for safe, evidence-based use.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
